ReviewCurrent cardiology reports2024
MicroRNAs and Cardiovascular Disease Risk.
Review in Current cardiology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Diagnostic Potential of Circulating miRNAs in Glioma: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- MicroRNAs in Cardiovascular Diseases and Forensic Applications: A Systematic Review of Diagnostic and Post-Mortem Implications.International journal of molecular sciences · 2026Pooled it
- Pooled it
- Identification of mitochondrial metabolism-associated tuberculosis key genes and construction of a diagnostic model based on WGCNA.Medical microbiology and immunology · 2026Article
- Environmental Toxic Metals and Metalloids Exposure and Cardiovascular Health: Current Evidence from Oxidative Stress and Inflammatory Biomarkers as Indicators of Subclinical Cardiovascular Effects.Antioxidants (Basel, Switzerland) · 2026Review
- From Parallel Programming to Bidirectional Crosstalk: The Brain-Kidney Axis in Cardiovascular-Kidney-Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
- An Optimized RT-qPCR Protocol for Comprehensive Analysis of microRNAs and mRNAs inNon-coding RNA · 2026Article
- Review
- Validation of circulating miR-323a-3p and miR-625-3p to classify hypertrophic cardiomyopathy in Friedreich's ataxia.Scientific reports · 2026Article
- MicroRNAs in Cardiovascular Diseases: Molecular Networks of Cellular Homeostasis, Inflammation, and Pathological Remodeling.International journal of molecular sciences · 2026Review
- MicroRNAs in Heart Failure Pathogenesis and Progression: Mechanistic Control, Biomarker Potential, and Translational Perspectives.Life (Basel, Switzerland) · 2026Review
- The miR-2110/Biochemistry and biophysics reports · 2026Article
- Leukocyte telomere length and circulating MiRNAs in relation to cardiovascular outcomes in older adults.BMC geriatrics · 2026Article
- Article
- Identification of Key Genes and miRNA-mRNA Regulatory Networks Associated with Intracranial Aneurysm Progression by Integrative Bioinformatics Analysis.Current medicinal chemistry · 2026Article
- MiR-150-5p attenuates heart failure by targeting MMP14 to regulate vascular smooth muscle cell function.Molecular and cellular biochemistry · 2026Article
- The silent dialogue between cells: regulatory roles of non-coding RNAs in cardiovascular disease.Frontiers in cell and developmental biology · 2026Review
- The pathophysiological role of MiRNAs in heart failure.Frontiers in cardiovascular medicine · 2026Review
- MicroRNA expression profile associated with coronary heart disease in patients with resistant arterial hypertension.Frontiers in molecular biosciences · 2026Article
- New Biomarkers in the Diagnosis and Prognosis of Dilated Cardiomyopathy: Pro-Resolving Lipids and miRNAs.Cells · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewMicroRNAs (miRNAs)-short, non-coding RNAs-play important roles in almost all aspects of cardiovascular biology, and changes in intracellular miRNA expression are indicative of cardiovascular disease development and progression. Extracellular miRNAs, which are easily measured in blood and can be reflective of changes in intracellular miRNA levels, have emerged as potential non-invasive biomarkers for disease. This review summarizes current knowledge regarding miRNAs as biomarkers for assessing cardiovascular disease risk and prognosis. RECENT
findingsNumerous studies over the last 10-15 years have identified associations between extracellular miRNA profiles and cardiovascular disease, supporting the potential use of extracellular miRNAs as biomarkers for risk stratification. However, clinical application of extracellular miRNA profiles has been hampered by poor reproducibility and inter-study variability that is due largely to methodological differences between studies. While recent studies indicate that circulating extracellular miRNAs are promising biomarkers for cardiovascular disease, evidence for clinical implementation is lacking. This highlights the need for larger, well-designed studies that use standardized methods for sample preparation, miRNA isolation, quantification, and normalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.